Maria Michele Byrne

Maria Michele Byrne

Auto-generated profile, based on publicly available information

Maria Michele Byrne

Department of Diabetes and Endocrinology, Mater Misericordiae University Hospital, Dublin, Ireland

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2015 in Diabetic Medicine
Verified
Journal Article
Closed access
PDF file
SBS. Bacon
S. Bacon
MKM. P. Kyithar
M. P. Kyithar
SRS. R. Rizvi
S. R. Rizvi
EDE. Donnelly
E. Donnelly
AMA. McCarthy
A. McCarthy
MBM. M. Byrne
M. M. Byrne

1 August 2015 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
SBSiobhan Bacon
Siobhan Bacon
JSJasmin Schmid
Jasmin Schmid
AMAilbhe McCarthy
Ailbhe McCarthy
JEJackie Edwards
Jackie Edwards
AFAileen Fleming
Aileen Fleming
MBMaria M. Byrne
Maria M. Byrne

23 June 2015 in Genes
Verified
Journal Article
Open access
PDF file
SBSiobhán Bacon
Siobhán Bacon
BEBritta Engelbrecht
Britta Engelbrecht
JSJasmin Schmid
Jasmin Schmid
SPShona Pfeiffer
Shona Pfeiffer
RGRoss Gallagher
Ross Gallagher
MBMaria M. Byrne
Maria M. Byrne
MicroRNA (miRNA) are a class of non-coding, 19–25 nucleotide RNA critical for network-level regulation of gene expression. miRNA serve as paracrine signaling molecules. Using an unbiased array approach, we previously identified elevated levels of miR-224 and miR-103 to be associated with a monogenic form of diabetes; HNF1A-MODY. miR-224 is a novel miRNA in the field of diabetes. We sought to explore the role of miR-224 as a potential biomarker in diabetes, and whether such diabetes-associated-miRNA can also be detected in the urine of patients. Absolute levels of miR-224 and miR-103 were determined in the urine of n = 144 individuals including carriers of a HNF1A mutation, participants with type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM) and normal controls. Expression levels were correlated with clinical and biochemical parameters. miR-224 was significantly elevated in the urine of carriers of a HNF1A mutation and participants with T1DM. miR-103 was highly expressed in urine across all diabetes cohorts when compared to controls. For both miR-224 and-103, we found a significant correlation between serum and urine levels (p < 0.01). We demonstrate that miRNA can be readily detected in the urine independent of clinical indices of renal dysfunction. We surmise that the differential expression levels of miR-224 in both HNF1A-MODY mutation carriers and T1DM may be an attempt to compensate for beta-cell demise.

18 July 2012 in BMC Endocrine Disorders
Verified
Journal Article
Open access
PDF file
SBSiobhán Bacon
Siobhán Bacon
MKMa Peyh Kyithar
Ma Peyh Kyithar
JSJasmin Schmid
Jasmin Schmid
SRSyed R Rizvi
Syed R Rizvi
Caroline BonnerCaroline Bonner
Caroline Bonner
MBMaria M Byrne
Maria M Byrne
Mutations in the transcription factor hepatocyte nuclear factor-1-alpha (HNF1A) result in the commonest type of maturity onset diabetes of the young (MODY). HNF1A-MODY carriers have reduced pancreatic beta cell mass, partially due to an increased rate of apoptosis. To date, it has not been possible to determine when apoptosis is occurring in HNF1A-MODY.We have recently demonstrated that beta cell apoptosis stimulates the expression of the pancreatic stone protein/regenerating (PSP/reg) gene in surviving neighbour cells, and that PSP/reg1A protein is subsequently secreted from these cells. The objective of this study was to determine whether serum levels of PSP/reg1A are elevated during disease progression in HNF1A-MODY carriers, and whether it may provide information regarding the onset of beta-cell apoptosis. We analysed serum PSP/reg1A levels and correlated with clinical and biochemical parameters in subjects with HNF1A-MODY, glucokinase (GCK-MODY), and type 1 diabetes mellitus. A control group of normoglycaemic subjects was also analysed. PSP/reg1A serum levels were significantly elevated in HNF1A-MODY (n = 37) subjects compared to controls (n = 60) (median = 12.50 ng/ml, IQR = 10.61-17.87 ng/ml versus median = 10.72 ng/ml, IQR = 8.94-12.54 ng/ml, p = 0.0008). PSP/reg1A correlated negatively with insulin levels during OGTT, (rho = −0.40, p = 0.02). Interestingly we noted a significant positive correlation of PSP/reg1A with age of the HNF1A-MODY carriers (rho = 0.40 p = 0.02) with an age of 25 years separating carriers with low and high PSP/reg1A levels. Patients with type 1 diabetes mellitus also had elevated serum levels of PSP/reg1A compared to controls, however this was independent of the duration of diabetes. Our data suggest that beta cell apoptosis contributes increasingly to the pathophysiology of HNF1A-MODY in patients 25 years and over. PSP/reg1A may be developed as a serum marker to detect increased beta-cell apoptosis, or its therapeutic response.

19 October 2016 in Journal of Medical Case Reports
Verified
Journal Article
Open access
PDF file
SRStephanie Rutledge
Stephanie Rutledge
MHMichele Harrison
Michele Harrison
MOMartin O’cOnnell
Martin O’cOnnell
TOTadhg O’dWyer
Tadhg O’dWyer
MBMaria M. Byrne
Maria M. Byrne
We report the case of a giant intrathyroidal parathyroid adenoma weighing 59 g in a young woman presenting acutely with severe hypercalcemia requiring correction and adequate preoperative management prior to surgery. Parathyroid adenomas account for 85 % of cases of primary hyperparathyroidism. Those weighing more than 3.5g are classified as giant parathyroid adenomas. There are only 25 cases of parathyroid adenomas weighing over 30g reported in the literature. With the wide availability of biochemical screening tests in Western countries, mildly elevated calcium levels are often discovered incidentally. Our case is unusual for the extreme level of hypercalcemia, the patient’s young age, and the weight of the adenoma, particularly in a developed country. A 21-year-old Irish woman presented with a 3-week history of an enlarging right-sided neck mass. There was no dysphagia, stridor, or symptoms of hyperthyroidism or hypercalcemia. On examination, there was a firm painless swelling in the right lobe of her thyroid. Her thyroid function tests were normal. Corrected serum calcium was markedly elevated at 3.96 mmol/L with hypophosphatemia of 0.35 mmol/L. She was treated with bisphosphonates and fluids administered intravenously. Her parathyroid hormone level was over 20 times the upper limit of normal. Ultrasound revealed a solid and cystic nodule in the lower pole of the right lobe of her thyroid. Parathyroid scintigraphy demonstrated a 5×4 cm lesion which concentrated tracer. A right-sided parathyroidectomy, right thyroid lobectomy, and level VI neck dissection were performed. An encapsulated multiloculated solid cystic mass weighing 59 g was removed. There was no definite infiltration of the capsule and MIB1 count was low at 1 % thus the specimen lacked the diagnostic features of carcinoma. On the third postoperative day, hungry bone syndrome developed and calcium replacement administered intravenously was required. At 1-year postoperative, she was weaned off calcium and alfacalcidol. A follow-up ultrasound showed unremarkable residual thyroid. Any patient with an isolated hypercalcemia warrants a thorough work-up. Hungry bone syndrome is a potentially avoidable condition; thus the clinician should be highly attuned to the risk of hungry bone syndrome post-parathyroidectomy, which correlates with the weight of the adenoma resected.

15 May 2013 in Diabetologia
Verified
Journal Article
Open access
PDF file
Caroline BonnerCaroline Bonner
Caroline Bonner
KNK. C. Nyhan
K. C. Nyhan
SBS. Bacon
S. Bacon
MKM. P. Kyithar
M. P. Kyithar
JSJ. Schmid
J. Schmid
MBM. M. Byrne
M. M. Byrne
HNF1A-MODY is a monogenic form of diabetes caused by mutations in the HNF1A gene. Here we identify, for the first time, HNF1A-MODY-associated microRNAs (miRNAs) that can be detected in the serum of HNF1A-MODY carriers.